Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease

1 Oct 2024

Abstract excerpt

INTRODUCTION: The aggregation and spread of hyperphosphorylated, pathological tau in the human brain is hypothesized to play a key role in Alzheimer's disease (AD) as well as other neurogenerative tauopathies. O-GlcNAcylation, an important post-translational modification of tau and many other proteins, is significantly decreased in brain tissue of AD patients relative to healthy controls. Increased tau...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Carbohydrate Chemistry and Synthesis
Share to Glycosylation and Glycoproteins Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39748851
DOI: 10.1002/trc2.70020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's diseasePMID 39748851Read ↗

Restoring the epigenome in Alzheimer's disease: advancing HDAC inhibitors as therapeutic agentsSemantic proximity Read ↗

Decoding tau acetylation in Alzheimer’s disease and tauopathies: from site-specific mechanisms to therapeutic horizonsSemantic proximity Read ↗

Structure of Crenezumab Complex with Aβ Shows Loss of β-HairpinSemantic proximity Read ↗

Acute increase of protein O-GlcNAcylation in mice leads to transcriptome changes in the brain opposite to what is observed in Alzheimer’s DiseaseSemantic proximity Read ↗

<i>O</i> -GlcNAcylation effect on Tau in modulating its seeding and cellular transmission in Alzheimer’s DiseaseSemantic proximity Read ↗

Repurposing Oncology Drugs for Alzheimer’s: Multi-Omic Convergence Targeting Cell-Cycle, Proteostasis, Immunometabolism, and SenescenceSemantic proximity Read ↗

O -GlcNAcylation ameliorates the pathological manifestations of Alzheimer’s disease by inhibiting necroptosisSemantic proximity Read ↗

Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivoSemantic proximity Read ↗

From APOE Genetics to AI-Designed Drug Candidates: An Integrated Pipeline for Oral, Brain-Penetrant ACAT1 Inhibitors in Alzheimer’s DiseaseSemantic proximity Read ↗

O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment.Semantic proximity Read ↗

Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trialsSemantic proximity Read ↗

PE859, a Novel Tau Aggregation Inhibitor, Reduces Aggregated Tau and Prevents Onset and Progression of Neural Dysfunction In VivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.